- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06788990
Fortifi-HN01: Eine Phase-2/3-Studie von Ficerafusp Alfa (BCA101) oder Placebo in Kombination mit Pembrolizumab in der ersten PD-L1-Pos, R oder M HNSCC (FORTIFI-HN01)
Eine multizentrische, randomisierte, doppelblinde, Phase-2/3-Studie mit Ficerafuspen-Alfa (BCA101) oder Placebo in Kombination mit Pembrolizumab zur Erstlinienbehandlung von PD-L1-positivem, wiederkehrenden oder metastasierten Kopf- und Hals-Plattenkarzinom
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.
Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:
- Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
- Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
- Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.
The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Medical Affairs
- Telefonnummer: 1-617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
Studienorte
-
-
-
Buenos Aires, Argentinien, C1190
- Rekrutierung
- CEMIC (Site # 2301)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Buenos Aires, Argentinien, C1425
- Rekrutierung
- ICM Center (Site # 2306)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Pilar, Argentinien, B1629ODT
- Rekrutierung
- Hospital Universitario Austral (Site # 2303)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rosario, Argentinien, CP2000
- Rekrutierung
- Sanatorio de la Mujer (Site # 2305)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Santa Fe, Argentinien, S2002KDT
- Rekrutierung
- Hospital Provincial del Centenario (Site # 2302)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekrutierung
- Chris O'Brien Lifehouse (Site#0302)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Kingswood, New South Wales, Australien, 2747
- Rekrutierung
- Nepean Hospital (Site #0306)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Waratah, New South Wales, Australien, 2298
- Rekrutierung
- Calvary Mater Newcastle (Site#0304)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Queensland
-
Southport, Queensland, Australien, 4215
- Rekrutierung
- Gold Coast University Hospital (Site #0305)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Tugun, Queensland, Australien, 4224
- Rekrutierung
- John Flynn Private Hospital (Site#0307)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Rekrutierung
- Austin Health (Site #0303)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
North Melbourne, Victoria, Australien, 3051
- Rekrutierung
- Peter Macallum Cancer Centre (Site#0301)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Western Australia
-
Murdoch, Western Australia, Australien, 6150
- Rekrutierung
- Fiona Stanley Hospital (Site#0308)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Bruges, Belgien, 8000
- Rekrutierung
- AZ St-Jan Brugge Oostende av (Campus Sint-Jan) (Site #1007)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Mons, Belgien, 7000
- Rekrutierung
- CHU Ambroise Paré (Site #1005)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Namur, Belgien, 5000
- Rekrutierung
- CHU UCL Namur, Site Ste. Elisabeth (Site #1002)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Namur, Belgien, 5530
- Rekrutierung
- CHU UCL Namur, Site Mont-Godinne (Site #1003)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Sint-Niklaas, Belgien, 9100
- Rekrutierung
- Vitaz (Site #1001)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Wilrijk, Belgien, 2610
- Rekrutierung
- ZAS Augustinus (Site #1006)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Barretos, Brasilien, 14784-400
- Rekrutierung
- Hospital de Amor de Barretos - Fundação Pio XII (Site # 2413)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Belém, Brasilien, 66063495
- Rekrutierung
- Centro de Tratamento Oncologico (Site # 2421)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Curitiba, Brasilien, 80810-050
- Rekrutierung
- CIONC-Centro Integrado de Oncologia de Curitiba (Site # 2404)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Fortaleza, Brasilien, 60430235
- Rekrutierung
- Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Ijuí, Brasilien, 98700-000
- Rekrutierung
- Oncosite - Centro de Pesquisa Clinica e Oncologia (Site # 2402)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Jaú, Brasilien, 17210-120
- Rekrutierung
- Fundação Doutor Amaral Carvalho (Site # 2411)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Natal, Brasilien, 59062-000
- Rekrutierung
- Liga Norte-Rio-Grandense Contra o Câncer (Site # 2422)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Passo Fundo, Brasilien, 99010-260
- Rekrutierung
- Hospital de Clínicas de Passo Fundo (Site # 2419)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Porto Alegre, Brasilien, 91350-200
- Rekrutierung
- Hospital Nossa Senhora da Conceicao (Site # 2403)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rio de Janeiro, Brasilien, 22250-905
- Rekrutierung
- Grupo Oncoclínicas (Site # 2412)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Santa Cruz do Sul, Brasilien, 96835-100
- Rekrutierung
- Hospital Ana Nery (Site # 2415)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Santa Lúcia, Brasilien, 30360680
- Rekrutierung
- Oncoclinicas do Brasil Serviços Médicos S.A - Oncocentro BH (Site # 2401)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São Caetano do Sul, Brasilien, 09541-270
- Rekrutierung
- Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São José do Rio Preto, Brasilien, 15090-000
- Rekrutierung
- Centro Integrado de Pesquisa do Hospital de Base de São José do Rio Preto/FUNFAR (Site # 2406)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brasilien, 01246-000
- Rekrutierung
- Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brasilien, 01509-900
- Rekrutierung
- A. C. Camargo Cancer Center (Site # 2409)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brasilien, 04014-002
- Rekrutierung
- IBCC Núcleo de Pesquisa e Ensino (Site # 2405)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brasilien, 04543
- Rekrutierung
- Oncoclínicas - SP (Site # 2416)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brasilien, 08270-120
- Rekrutierung
- Hospital Santa Marcelina (Site # 2418)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Vitoria ES
-
Santa Cecília, Vitoria ES, Brasilien, 29043-260
- Rekrutierung
- AFECC Hospital Santa Rita de Cassia (Site # 2420)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Aachen, Deutschland, 52074
- Rekrutierung
- Universitaetsklinikum Aachen AOeR (Site #0710)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Berlin, Deutschland, 12200
- Rekrutierung
- Charite - Campus Benjamin Franklin (Site # 0701)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Berlin, Deutschland, 12351
- Rekrutierung
- Vivantes Klinikum Neukoelln (Site # 0714)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Braunschweig, Deutschland, 38114
- Rekrutierung
- Staedtisches Klinikum Braunschweig gGmbH (Site # 0709)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Chemnitz, Deutschland, 09116
- Rekrutierung
- Klinikum Chemnitz gGmbH (Site # 0705)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Dresden, Deutschland, 01067
- Rekrutierung
- Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt (Site #0707)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Dresden, Deutschland, 01307
- Rekrutierung
- Universitaetsklinikum Carl Gustav Carus TU Dresden (Site # 0711)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Düsseldorf, Deutschland, 40225
- Rekrutierung
- Heinrich-Heine-Universitaet Duesseldorf (Site #0706)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Essen, Deutschland, 45147
- Rekrutierung
- Universitaetsklinikum Essen (Site # 0716)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Göttingen, Deutschland, 37075
- Rekrutierung
- Universitaetsmedizin Goettingen (Site # 0708)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Hanover, Deutschland, 30625
- Rekrutierung
- Medizinische Hochschule Hannover (Site # 0718)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Karlsruhe, Deutschland, 76137
- Rekrutierung
- Vincentius-Diakonissen-Kliniken gAG/St. Vincentius-Kliniken (Site #0717)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
München, Deutschland, 81675
- Rekrutierung
- Technische Universität München School of Medicine (Site # 0715)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Stuttgart, Deutschland, 70174
- Rekrutierung
- Klinikum Stuttgart-Katharinenhospital (Site # 0703)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Ulm, Deutschland, 89075
- Rekrutierung
- Universitaetsklinikum Ulm (Site # 0702)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Amiens, Frankreich, 80480
- Rekrutierung
- CHU Amiens - Hopital Sud (Site #0809)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Bordeaux, Frankreich, 33075
- Rekrutierung
- CHU de Bordeaux (Site # 0812)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Lille, Frankreich, 59000
- Rekrutierung
- Centre Oscar Lambret (Site # 0804)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Lyon, Frankreich, 69004
- Rekrutierung
- Centre Hospitalier de la Croix Rousse (Site #0810)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Paris, Frankreich, 75005
- Rekrutierung
- Institut Curie - site de Paris (Site # 0813)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rennes, Frankreich, 35042
- Rekrutierung
- CRLCC Eugene Marquis (Site #0805)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Saint-Grégoire, Frankreich, 35760
- Rekrutierung
- Les Hopitaux Prives Rennais - Saint-Gregoire (Site #0807)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Strasbourg, Frankreich, 67200
- Rekrutierung
- Centre Regional Lutte Contre Le Cancer - PAUL STRAUSS (Site #0808)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Toulouse, Frankreich, 31059
- Rekrutierung
- IUCT-Oncopole (Site # 0811)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Vandœuvre-lès-Nancy, Frankreich, 54519
- Rekrutierung
- ICL - Alexis Vautrin (Site #0806)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Villejuif, Frankreich, 94805
- Rekrutierung
- Institut Gustave Roussy (Site #0801)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Athens, Griechenland, 12461
- Rekrutierung
- U.G.H. ATTIKON - General Hospital of West Attica "H AGIA VARVARA" (Site # 1701)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Larissa, Griechenland, 41110
- Rekrutierung
- University General Hospital of Larissa (Site # 1702)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Madurai, Indien, 625107
- Rekrutierung
- Meenakshi Mission Hospital & Research Centre (Site # 3003)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Sūrat, Indien, 395004
- Rekrutierung
- Nirmal Hospital (Site # 3002)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Cork, Irland, T12 DC4A
- Rekrutierung
- Cork University Hospital - Consultants Private Clinic (Site # 0603)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Dublin, Irland, D08 NHY1
- Rekrutierung
- Trinity College Dublin (TCD) - St. James's Hospital (SJH) (Site #0602)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Dublin, Irland, D09 V2N0
- Rekrutierung
- Beaumont Hospital (Site #0601)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Beersheba, Israel, 84101
- Rekrutierung
- Soroka Medical Center (Site # 1901)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Jerusalem, Israel, 9112001
- Rekrutierung
- Hadassah Medical Center (Site # 1903)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Petah Tikva, Israel, 49100
- Rekrutierung
- Rabin Medical Center (Site # 1904)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Tel Aviv, Israel, 6423906
- Rekrutierung
- Sourasky Medical Center (Site # 1902)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Bologna, Italien, 40138
- Rekrutierung
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi (Site #0904)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Cagliari, Italien, 09121
- Rekrutierung
- ARNAS G. Brotzu (Site # 913)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Florence, Italien, 50134
- Rekrutierung
- Azienda Ospedaliera Universitaria Careggi (Site #0911)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Milan, Italien, 20132
- Rekrutierung
- Ospedale San Raffaele (Site #0907)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Milan, Italien, 20133
- Rekrutierung
- Fondazione IRCCS Istituto Nazionale dei Tumori (Site #0901)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Milan, Italien, 20142
- Rekrutierung
- ASST Santi Paolo e Carlo, Ospedale San Paolo Polo Universitario (Site #0905)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Milan, Italien, 20162
- Rekrutierung
- Azienda Socio Sanitaria Territoriale Niguarda (Site # 0912)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Naples, Italien, 80131
- Rekrutierung
- Istituto Nazionale Tumori Fondazione G. Pascale (Site #0915)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Naples, Italien, 80131
- Rekrutierung
- UOC Oncoematologia AOU - University Luigi Vanvitelli (Site # 0916)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Padova, Italien, 35128
- Rekrutierung
- IOV - Istituto Oncologico Veneto IRCCS (Site # 0910)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Palermo, Italien, 90127
- Rekrutierung
- Policlinico P. Giaccone di Palermo (Site #0908)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Pavia, Italien, 27100
- Rekrutierung
- Fondazione IRCCS Policlinico San Matteo (Site # 0903)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Pisa, Italien, 56126
- Rekrutierung
- Azienda Ospedaliero Universitaria Pisana (Site # 0909)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rome, Italien, 00161
- Rekrutierung
- Azienda Ospedaliero-Universitaria Policlinico Umberto I (Site #0917)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rome, Italien, 00168
- Rekrutierung
- Fondazione Policlinico Universitario - Agostino Gemelli (Site #0918)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rome, Italien, 00186
- Rekrutierung
- Fatebenefratelli Isola Tiberina, Gemelli Isola (Site #0906)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rozzano, Italien, 20089
- Rekrutierung
- Humanitas Mirasole S.p.A (Site # 0919)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Siena, Italien, 53100
- Rekrutierung
- A.O.U. Senese Policlinico Santa Maria alle Scotte (Site # 0902)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Kōtoku, Japan, 135-8550
- Rekrutierung
- Cancer Institute Hospital of JFCR (Site # 3107)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Toronto, Kanada, M4N 3M5
- Rekrutierung
- Sunnybrook Health Sciences Centre (Site # 0204)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- Rekrutierung
- BC Cancer - Vancouver (Site #0202)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X 0C1
- Rekrutierung
- Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (Site #0203)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
George Town, Malaysia, 11200
- Rekrutierung
- Mount Miriam Cancer Hospital (Site # 2802)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Kuala Lumpur, Malaysia, 50586
- Rekrutierung
- Hospital Kuala Lumpur (Site # 2803)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Kuala Lumpur, Malaysia, 59100
- Rekrutierung
- University Malaya Medical centre (Site # 2805)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Kuching, Malaysia, 93200
- Rekrutierung
- Sarawak General Hospital (Site # 2801)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Pulau Pinang, Malaysia, 10450
- Rekrutierung
- Hospital Pulau Pinang (Site # 2804)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Christchurch, Neuseeland, 8011
- Rekrutierung
- Christchurch Hospital NZ (Site #0401)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rotorua, Neuseeland, 3010
- Rekrutierung
- Rotorua Hospital (Site#0402)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Gdansk, Polen, 80-214
- Rekrutierung
- UNIWERSYTECKIE CENTRUM KLINICZNE (Site #1401)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Gliwice, Polen, 44-102
- Rekrutierung
- Centrum Onkologii-Instytut im.M.Sklodowskiej Curie (Site # 1405)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Katowice, Polen, 40-519
- Rekrutierung
- Pratia Onkologia Katowice (Site #1403)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Konin, Polen, 62-500
- Rekrutierung
- Przychodnia Lekarska Komed (Site #1407)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Krakow, Polen, 31-826
- Rekrutierung
- Szpital Specjalistyczny im. L.Rydygiera w Krakowie (Site #1404)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Siedlce, Polen, 08-110
- Rekrutierung
- Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o. (Site #1402)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Warsaw, Polen, 02-781
- Rekrutierung
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curiee - Panstwowy Instytut (Site #1406)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Braga, Portugal, 4710-243
- Rekrutierung
- Centro Clínico Académico de Braga (Site #1506)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Coimbra, Portugal
- Rekrutierung
- Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (Site #1503)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Lisbon, Portugal, 1099-023
- Rekrutierung
- Instituto Português de Oncologia Lisboa (Site #1508)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Portimão, Portugal, 8500-338
- Rekrutierung
- Centro Hospitalar Algarve (Site #1501)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Porto, Portugal, 4200-072
- Rekrutierung
- Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (Site #1505)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Porto, Portugal, 4200-319
- Rekrutierung
- Centro Hospitalar Universitario de Sao Joao (Site #1507)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Senhora da Hora, Portugal, 4464-509
- Rekrutierung
- Unidade Local de Saude de Matosinhos, E.P.E. - Hospital Pedro Hispano (Site #1502)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Vila Nova de Gaia, Portugal, 4434-502
- Rekrutierung
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E. (Site # 1504)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Fribourg, Schweiz, 1752
- Rekrutierung
- HFR Fribourg Kantonsspital Fribourg (Site # 1803)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Geneva, Schweiz, 1205
- Rekrutierung
- Hopitaux Universitaires de Geneve (Site # 1802)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Lausanne, Schweiz, 1011
- Rekrutierung
- Centre Hospitalier Universitaire Vaudois (CHUV) (Site # 1801)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Novena, Singapur, 308433
- Rekrutierung
- Tan Tock Seng Hospital (Site # 2902)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Singapore, Singapur, 168583
- Rekrutierung
- National Cancer Centre Singapore (Site # 2901)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Badalona, Spanien, 8916
- Rekrutierung
- ICO Badalona - Hospital Universitari Germans Trias i Pujol (Site # 1311)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanien, 08035
- Rekrutierung
- Hospital Universitari Vall d'Hebron (Site #1301)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanien, 08036
- Rekrutierung
- Hospital Clinic de Barcelona (Site #1305)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanien, 08041
- Rekrutierung
- Hospital de la Santa Creu I Sant Pau Site #1304
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanien, 08908
- Rekrutierung
- Institut Catala d'Oncologia (Site # 1302)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Madrid, Spanien, 28027
- Rekrutierung
- Clinica Universidad de Navarra- Madrid (Site #1310)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Madrid, Spanien, 28041
- Rekrutierung
- Hospital Universitario 12 De Octubre (Site #1303)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Pamplona, Spanien, 31008
- Rekrutierung
- Clinica Universidad de Navarra (Site #1306)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Santander, Spanien, 39008
- Rekrutierung
- Hospital Universitario Marques de Valdecilla (HUMV) (Site #1309)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Valencia, Spanien, 46010
- Rekrutierung
- Hospital Clinico Universitario de Valencia (Site #1307)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Valencia, Spanien, 46014
- Rekrutierung
- Hospital General Universitario de Valencia (Site #1308)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Busan, Südkorea, 49267
- Rekrutierung
- Kosin University Gospel Hospital (Site # 2707)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Goyang-si, Südkorea, 10408
- Rekrutierung
- National Cancer Center (Site # 2704)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Hwasun, Südkorea, 58128
- Rekrutierung
- Chonnam National University Hwasun Hospital (Site # 2705)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Seongnam, Südkorea, 13620
- Rekrutierung
- Seoul National University Bundang Hospital (Site # 2706)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Seoul, Südkorea, 3080
- Rekrutierung
- Seoul National University Hospital (Site # 2701)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Seoul, Südkorea, 3722
- Rekrutierung
- SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Seoul, Südkorea, 6351
- Rekrutierung
- Samsung Medical Center (Site # 2703)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Changhua, Taiwan, 50006
- Rekrutierung
- Changhua Christian Medical Foundation Changhua Christian Hospital (Site # 2602)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Kaohsiung City, Taiwan, 807
- Rekrutierung
- Kaohsiung Medical University Chung-Ho Memorial Hospital (Site # 2601)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-421
- E-Mail: FORTIFI_inquiries@bicara.com
-
Taichung, Taiwan, 40447
- Rekrutierung
- China Medical University Hospital (CMUH) (Site # 2603)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Taipei, Taiwan, 10002
- Rekrutierung
- National Taiwan University Hospital (Site # 2604)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Bangkok, Thailand, 10400
- Rekrutierung
- Phramongkutklao Hospital (Site # 2505)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Bangkok, Thailand, 10400
- Rekrutierung
- Rajavithi Hospital (Site # 2504)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Chiang Mai, Thailand, 50200
- Rekrutierung
- Maharaj Nakorn Chiang Mai Hospital (Site # 2506)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Dusit, Thailand, 10300
- Rekrutierung
- Vajira Hospital (Site # 2503)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Hat Yai, Thailand, 90110
- Rekrutierung
- Songklanagarind Hospital (Site # 2502)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Hradec Králové, Tschechien, 500 03
- Rekrutierung
- Fakultni Nemocnice Hradec Kralove (FNHK) (Site # 2101)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Prague, Tschechien, 15006
- Rekrutierung
- Fakultni nemocnice Motol a Homolka (Site #2102)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Ankara, Türkei (türkiye), 6100
- Rekrutierung
- Hacettepe University Medical Faculty (Site # 1201)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Ankara, Türkei (türkiye), 6520
- Rekrutierung
- Memorial Ankara Hospital (Site # 1202)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Antalya, Türkei (türkiye), 7020
- Rekrutierung
- Memorial Antalya Hastanesi (Site # 1204)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Istanbul, Türkei (türkiye), 34098
- Rekrutierung
- Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Izmir, Türkei (türkiye), 35330
- Rekrutierung
- Dokuz Eylul University Medical School (Site # 1206)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Rekrutierung
- University of Alabama Hospital (Site # 0137)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Rekrutierung
- Mayo Clinic Hospital (Site #0147)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
California
-
La Jolla, California, Vereinigte Staaten, 92093
- Rekrutierung
- UC San Diego Moores Cancer Center (Site #0107)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Los Angeles, California, Vereinigte Staaten, 90095
- Rekrutierung
- UCLA Department of Medicine - Hematology/Oncology (Site #0106)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Sacramento, California, Vereinigte Staaten, 95817
- Rekrutierung
- UC Davis (Site#0144)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
San Francisco, California, Vereinigte Staaten, 94143
- Rekrutierung
- University of California San Francisco (Site #0130)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Stanford, California, Vereinigte Staaten, 94305
- Rekrutierung
- Stanford Cancer Institute (Site #0150)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rekrutierung
- Rocky Mountain Cancer Centers, LLP (Site #0122)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- Rocky Mountain Regional VAMC (Site #0124)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- Rekrutierung
- ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Rekrutierung
- Mayo Clinic Florida (Site #0148)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Palm Bay, Florida, Vereinigte Staaten, 32901
- Rekrutierung
- Cancer Care Centers of Brevard (Site #0136)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Tampa, Florida, Vereinigte Staaten, 33612
- Rekrutierung
- Moffit Cancer Center (Site #0105)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60064
- Rekrutierung
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa Hospitals & Clinics (Site#0140)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Kansas
-
Westwood, Kansas, Vereinigte Staaten, 66205
- Rekrutierung
- University of Kansas Medical Center Research Institute, Inc. (Site #0149)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky, Markey Cancer Center (Site # 109)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- Norton Cancer Institute (Site#0111)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- The University of Louisville, James Graham Brown Cancer Center (Site#0115)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland Medical Group (Site #0112)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital (Site #0131)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Boston, Massachusetts, Vereinigte Staaten, 02136
- Rekrutierung
- Dana-Farber Cancer Institute (Site#0101)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- University of Michigan (Site # 161)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Minnesota
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Rekrutierung
- Site #0156
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic Cancer Center - Rochester (Site #0146)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine (Site #0114)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Rekrutierung
- Hackensack Meridian Health (Site # 119)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Newark, New Jersey, Vereinigte Staaten, 07103
- Rekrutierung
- Rutgers- Cancer Institute (Site #0145)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
New York
-
New York, New York, Vereinigte Staaten, 10003
- Rekrutierung
- Mount Sinai (Site #0155)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Memorial Sloan Kettering Cancer Center (Site#0142)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27703
- Rekrutierung
- Duke University Health System (Site#0118)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Ohio
-
Canton, Ohio, Vereinigte Staaten, 44708
- Rekrutierung
- Mercy Hospital (Site#0154)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Cincinnati, Ohio, Vereinigte Staaten, 45221
- Rekrutierung
- University of Cincinnati Cancer Institute (Site#0117)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- University Hospitals Seidman Cancer Center (Site #0151)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic (Site #0108)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97213
- Rekrutierung
- Providence Portland Medical Center (Site #0113)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15206
- Rekrutierung
- UPMC Hillman Cancer Center (Site #0103)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15240
- Rekrutierung
- VA Pittsburgh Healthcare System (Site #0123)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rekrutierung
- Lifespan Cancer Institute (Site #0132)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina (MUSC) (Site#0104)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- SCRI-Oncology Partners (Site#0126)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt-Ingram Cancer Center (Site #0116)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77005
- Rekrutierung
- MD Anderson Cancer Center (Site#0102)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Waco, Texas, Vereinigte Staaten, 676712
- Rekrutierung
- SCRI- Texas Oncology- Central South (Site #0152)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22904
- Rekrutierung
- University of Virginia (Site#0134)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Richmond, Virginia, Vereinigte Staaten, 23219
- Rekrutierung
- Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Richmond, Virginia, Vereinigte Staaten, 23249
- Rekrutierung
- Richmond Department of Veterans Affairs (Site #0138)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Washington
-
Edmonds, Washington, Vereinigte Staaten, 98026
- Rekrutierung
- Swedish Cancer Institute - North Campus Edmonds (Site # 0160)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Seattle, Washington, Vereinigte Staaten, 98104
- Rekrutierung
- Swedish Cancer Institute (Site # 0159)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Seattle, Washington, Vereinigte Staaten, 98109
- Rekrutierung
- University of Washington - Seattle Cancer Care Alliance (Site #0125)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Vancouver, Washington, Vereinigte Staaten, 98684
- Rekrutierung
- Northwest Cancer Specialists, PC (Site#0120)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53705
- Rekrutierung
- William S. Middleton Memorial Veteran's Hospital (Site #0141)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin Hospital and Clinics (Site #0157)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53233
- Rekrutierung
- Advocate Aurora Research Institute (Site # 0153)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Aberdeen, Vereinigtes Königreich, AB25 2ZN
- Rekrutierung
- Aberdeen Royal Infirmary (Site #0504)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Birmingham, Vereinigtes Königreich, B15 2TH
- Rekrutierung
- University Hospitals Birmingham (Queen Elizabeth Hospital) (Site #0512)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Cambridge, Vereinigtes Königreich, CB2 0QQ
- Rekrutierung
- Cambridge University Hospitals (Site #0513)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Glasgow, Vereinigtes Königreich, G12 0YN
- Rekrutierung
- Beatson West of Scotland Cancer Centre (Site # 0510)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Leeds, Vereinigtes Königreich, LS9 7TF
- Rekrutierung
- St James University Hospital Leeds (Site #0511)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Liverpool, Vereinigtes Königreich, L7 8YA
- Rekrutierung
- Clatterbridge Cancer Center NHS Foundation (Site #0507)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
London, Vereinigtes Königreich, SW3 6JJ
- Rekrutierung
- Royal Marsden Hospital - Chelsea (Site #0505)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
London, Vereinigtes Königreich, WC1E 6AG
- Rekrutierung
- University College London Hospital (Site #0502)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Manchester, Vereinigtes Königreich, M20 4BX
- Rekrutierung
- The Christie Hospital (Site #0508)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Middlesex, Vereinigtes Königreich, HA6 2RN
- Rekrutierung
- Mount Vernon Cancer Centre (Site #0506)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Newcastle upon Tyne, Vereinigtes Königreich, NE7 7DN
- Rekrutierung
- Newcastle University (Site # 509)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Nottingham, Vereinigtes Königreich, NG5 1PB
- Rekrutierung
- Nottingham University Hospitals City Campus (Site #0503)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Oxford, Vereinigtes Königreich, OX3 7LE
- Rekrutierung
- Churchill Hospital (Site #0515)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Portsmouth, Vereinigtes Königreich, PO6 3LY
- Rekrutierung
- Queen Alexandra Hospital (Site # 0514)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Sutton, Vereinigtes Königreich, SM2 5PT
- Rekrutierung
- Royal Marsden Hospital- London (Site # 0501)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Salzburg, Österreich, 5020
- Rekrutierung
- Hematology and Medical Oncology, Paracelsus Medical University (Site #1602)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
Vienna, Österreich, 1090
- Rekrutierung
- Medical University Vienna (Site #1601)
-
Kontakt:
- Principal Investigator
- Telefonnummer: 617-468-4219
- E-Mail: FORTIFI_inquiries@bicara.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥18 years on the day the Informed Consent Form is signed.
- Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
- No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
- Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
- PD-L1 CPS ≥1.
- Measurable disease based on RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function, as defined in the protocol.
Exclusion Criteria:
- Disease suitable for local therapy administered with curative intent.
- Prior treatment with anti-TGFβ therapy.
- Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
- Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
- Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
- Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
- Life expectancy less than 3 months.
- Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
- Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
- Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
- Active autoimmune disease requiring systemic treatment in the past 2 years.
- Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
- Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
- Known history of human immunodeficiency virus (HIV).
- Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
- Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
- Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
- Use of a live or live attenuated vaccine within 4 weeks prior to Screening.
Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Phase 2 Arm A
ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W) |
Investigational Immunotherapy agent used in combination with investigational agent |
|
Experimental: Phase 2 Arm B
ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W |
Investigational Immunotherapy agent used in combination with investigational agent |
|
Placebo-Komparator: Phase 2 Arm C
placebo QW + pembrolizumab 200 mg Q3W |
Immunotherapy agent used in combination with investigational agent Placebo Control |
|
Experimental: Phase 3 OBD Arm
ficerafusp alfa OBD + pembrolizumab 200 mg Q3W |
Investigational Immunotherapy agent used in combination with investigational agent |
|
Placebo-Komparator: Phase 3 Arm C
placebo QW + pembrolizumab 200 mg Q3W |
Immunotherapy agent used in combination with investigational agent Placebo Control |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Zeitfenster: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
To assess safety and tolerability of ficerafusp alfa with pembrolizumab. |
Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
|
Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)
Zeitfenster: Approximately 1 year.
|
ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR. |
Approximately 1 year.
|
|
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Zeitfenster: Approximately 2 years.
|
ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR. |
Approximately 2 years.
|
|
Phase 3 - Overall Survival (OS)
Zeitfenster: Approximately 3 years.
|
OS: Defined as the time from the randomization to death due to any cause. |
Approximately 3 years.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Zeitfenster: Approximately 1 year.
|
DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR. |
Approximately 1 year.
|
|
Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Zeitfenster: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
To assess safety and tolerability of ficerafusp alfa with pembrolizumab. |
Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
|
Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.
Zeitfenster: Approximately 3 years.
|
PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first. |
Approximately 3 years.
|
|
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Zeitfenster: Approximately 3 years.
|
ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS). |
Approximately 3 years.
|
|
Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Zeitfenster: Approximately 3 years.
|
DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR. |
Approximately 3 years.
|
|
Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.
Zeitfenster: Approximately 3 years.
|
Clinical Benefit Rate: For subject who demonstrated CR + PR + SD>6 months per RECIST 1.1 by BICR. |
Approximately 3 years.
|
|
Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.
Zeitfenster: Approximately 3 years.
|
ORR, per RECIST 1.1 as determined by investigator's assessment. |
Approximately 3 years.
|
|
Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.
Zeitfenster: Approximately 3 years.
|
DOR, per RECIST 1.1 as determined by investigator's assessment. |
Approximately 3 years.
|
|
Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.
Zeitfenster: Approximately 3 years.
|
PFS, per RECIST 1.1 as determined by investigator's assessment. |
Approximately 3 years.
|
|
Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)
Zeitfenster: Approximately 3 years.
|
To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab. TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. |
Approximately 3 years.
|
|
Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.
Zeitfenster: Approximately 3 years.
|
To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab. TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden. |
Approximately 3 years.
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Knochenerkrankungen
- Erkrankungen des Bewegungsapparates
- Neubildungen nach Standort
- Neubildungen
- Genetische Krankheiten, angeboren
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Karzinom
- Otorhinolaryngologische Erkrankungen
- Karzinom, Plattenepithel
- Osteochondrodysplasien
- Knochenerkrankungen, Entwicklungs
- Angeborene, erbliche und neonatale Krankheiten und Anomalien
- Plattenepithelkarzinom von Kopf und Hals
- Kopf-Hals-Neubildungen
- Kehlkopferkrankungen
- Camuratii-Ungelmann-Syndrom
- Pembrolizumab
Andere Studien-ID-Nummern
- BCA101X301
- 2024-519654-37-00 (Ctis)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .